Orano Med is a clinical-stage biotechnology company developing a new generation of targeted cancer therapies using the unique properties of lead-212, a rare radioisotope that emits alpha radiation and shows promising potential for destroying cancer cells.
The company is developing a portfolio of radioligand therapies combining lead-212 with various targeting agents, as part of both clinical and preclinical studies. Orano Med also operates lead-212 production facilities, as well as laboratories and R&D centers in France and the United States.
